These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34012779)

  • 1. Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.
    Ding PN; Roberts TL; Chua W; Becker TM; Caixeiro N; de Souza P; Gao B; Lee CK; Itchins M; Westman H; Clarke S; Blinman P; Kao S; John T; Leal JL; Bray VJ
    Transl Lung Cancer Res; 2021 Apr; 10(4):1623-1634. PubMed ID: 34012779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.
    Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL
    Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
    Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
    Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
    Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.
    Tung PH; Chiu TH; Huang AC; Ju JS; Huang CH; Wang CC; Ko HW; Chung FT; Hsu PC; Fang YF; Guo YK; Kuo CS; Yang CT
    Ther Adv Med Oncol; 2024; 16():17588359231222604. PubMed ID: 38249338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
    Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
    Front Oncol; 2022; 12():863666. PubMed ID: 35785185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
    Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
    Front Oncol; 2021; 11():621992. PubMed ID: 33718183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib.
    Wang Y; He Y; Tian P; Wang W; Wang K; Chuai S; Li Y; Zhao S; Wang Y; Li W
    Transl Lung Cancer Res; 2020 Oct; 9(5):1952-1962. PubMed ID: 33209615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard dose osimertinib for erlotinib refractory T790M-negative
    Arulananda S; Do H; Rivalland G; Loh Z; Musafer A; Lau E; Mitchell P; Dobrovic A; John T
    J Thorac Dis; 2019 May; 11(5):1756-1764. PubMed ID: 31285867
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
    Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.
    Watanabe K; Saito R; Miyauchi E; Nagashima H; Nakamura A; Sugawara S; Tanaka N; Terasaki H; Fukuhara T; Maemondo M
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
    Ikushima H; Sakatani T; Usui K
    Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
    Pan G; Chen K; Yu X; Sheng J; Fan Y
    Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib in NSCLC: Real-World Data From New Zealand.
    So YJ; Fraser A; Rivalland G; McKeage M; Sullivan R; Cameron L
    JTO Clin Res Rep; 2020 Jun; 1(2):100022. PubMed ID: 34589929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
    Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
    Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
    Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
    J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.